Current Report Filing (8-k)

Date : 05/08/2019 @ 11:44AM
Source : Edgar (US Regulatory)
Stock : Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Quote : 62.98  0.0 (0.00%) @ 5:00AM

Current Report Filing (8-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 7, 2019

 


 

Biohaven Pharmaceutical Holding Company Ltd.

(Exact name of registrant as specified in its charter)

 

British Virgin Islands

 

001-38080

 

Not applicable

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

c/o Biohaven Pharmaceuticals, Inc.

215 Church Street

New Haven, Connecticut 06510

(Address of principal executive offices, including zip code)

 

(203) 404-0410

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol

 

Name of each exchange on which registered

Common Shares, no par value

 

BHVN

 

New York Stock Exchange

 

 

 


 

Item 7.01 Regulation FD Disclosure.

 

As previously announced, in conjunction with the 2019 Annual Meeting of the American Academy of Neurology, on May 7, 2019 at 7:00 pm EDT Biohaven Pharmaceutical Holding Company Ltd. (the “Company”) is hosting an offsite investor event at which expanded data from the Company’s recently completed rimegepant 75 mg Zydis® ODT Phase 3 clinical trial will be presented, including a discussion by a migraine expert panel (the “Event”). A copy of the presentation that will accompany the Event is attached as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

 

The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
Number

 

Exhibit Description

99.1

 

Investor Presentation, dated May 7, 2019.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Biohaven Pharmaceutical Holding Company Ltd.

 

 

 

 

By:

/s/ Vlad Coric, M.D.

Date: May 7, 2019

 

Vlad Coric, M.D.

Chief Executive Officer

 

3


Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)
Historical Stock Chart

1 Year : From Jun 2018 to Jun 2019

Click Here for more Biohaven Pharmaceutical Holding Company Ltd. Charts.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)
Intraday Stock Chart

Today : Sunday 16 June 2019

Click Here for more Biohaven Pharmaceutical Holding Company Ltd. Charts.

Latest BHVN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.